Abacus Health Products

Abacus Health Products in its going public transaction by way of a reverse takeover, US$15 million concurrent financing and listing on the Canadian Securities Exchange

Client

Abacus Health Products, Inc.

Value

US$15 million

Service

Mergers and Acquisitions

Date Closed

January 2019

Lead Office

Montréal

On January 29, 2019, Abacus Health Products, Inc. (“Abacus”), a Delaware corporation, completed its previously announced going public transaction by way of a reverse takeover of an Ontario corporation formerly known as World Wide Inc. and renamed Abacus Health Products, Inc. In connection with the transaction, Abacus completed a private placement for gross proceeds of US$15 million. The subordinate voting shares of the resulting issuer became listed on the Canadian Securities Exchange following the closing of the transaction.

Abacus is a company engaged in the development and commercialization of over-the-counter (OTC) topical pain-relieving medications registered with the U.S. Food and Drug Administration which contain CBD, a cannabinoid-rich hemp extract.

Osler, Hoskin & Harcourt LLP represented Abacus with a team consisting of Eric Levy, Jason Comerford, Bastien Gauthier, Jie Chai, Jean-Philippe Bertrand (Corporate), Manon Thivierge and Kevin Colan (Tax).